Form D · Biotechnology
Radiance Biopharma, Inc.
Boston, MA · CIK 0002013052
Offering snapshot reported Feb 28, 2024 · SEC filing
- Reported sold
- $250K Offering amount: $30M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 13, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2024 | Initial | $250,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-506309
Convertible Promissory Note.
Source: Form D, filed Feb 28, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Brooks | Director, Executive |
| Marc Lippman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Boston Place Suite 2600
Boston, MA, 02108
Boston, MA, 02108